keyword
MENU ▼
Read by QxMD icon Read
search

HPV vaccines safety

keyword
https://www.readbyqxmd.com/read/29442400/what-information-can-change-the-attitude-of-teachers-toward-the-human-papillomavirus-vaccine
#1
Masaharu Kamada, Hiroaki Inui, Tomohiro Kagawa, Ayuka Mineda, Takao Tamura, Tomohito Fujioka, Takahiro Motoki, Hiroki Hirai, Eiichi Ishii, Minoru Irahara
AIM: We conducted a self-administered survey on the perception of teachers toward human papillomavirus (HPV) vaccine to determine the ways to increase their willingness to encourage its use. METHODS: Answers were obtained both prior to and after having the teachers read five brief information articles: (i) cervical cancer knowledge, (ii) vaccine knowledge, (iii) result of a survey in Nagoya, (iv) news report of the World Health Organization statement and (v) articles written by Dr Muranaka, a journalist...
February 14, 2018: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/29428270/-ten-years-of-human-papilloma-virus-vaccination-from-dermatology-to-oncology-via-the-infectious-diseases-department
#2
Fernando A Moraga-Llop
Human papilloma virus (HPV) was first identified in dermatology, and it was subsequently demonstrated that is was required for the development of uterine cervical cancer and other tumours, after a persistent infection by any of its oncogenic genotypes. Ten years ago, the most common infections and cancers associated with HPV could be prevented by immunisation with 2vaccines, one bivalent, and another tetravalent, and having just marketed a nonavalent one. During the period 2007-2008, the HPV vaccine was included in the Autonomous Communities vaccination calendar, and it is the second vaccine, after that of Hepatitis B, that prevents cancer...
February 7, 2018: Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría (A.E.P.)
https://www.readbyqxmd.com/read/29428178/evaluation-on-the-persistence-of-anti-hpv-immune-responses-to-the-quadrivalent-hpv-vaccine-in-chinese-females-and-males-up-to-3-5%C3%A2-years-of-follow-up
#3
Teng Huang, Youping Liu, Yanping Li, Yuqin Liao, Qiong Shou, Minghuan Zheng, Xueyan Liao, Rongcheng Li
BACKGROUND: This was an extension study of a randomized, double-blind, placebo-controlled immunogenicity and safety study of the quadrivalent human papillomavirus (qHPV) (HPV 6, 11, 16, and 18) vaccine conducted in Chinese female subjects aged 9-45 years and male subjects aged 9-15 years. To investigate the persistence of anti-HPV 6, -11, -16, and -18 responses among Chinese subjects, subjects enrolled in the base study were followed up at around month 42 (approximately 3.5 years after vaccination)...
February 7, 2018: Vaccine
https://www.readbyqxmd.com/read/29428177/caregiver-and-adolescent-factors-associated-with-delayed-completion-of-the-three-dose-human-papillomavirus-vaccination-series
#4
Lea E Widdice, Rebecca Hoagland, S Todd Callahan, Jessica A Kahn, Christopher J Harrison, Barbara A Pahud, Sharon E Frey, Andrea A Berry, Karen L Kotloff, Kathryn M Edwards, Mark J Mulligan, Jon Sudman, Aya Nakamura, David I Bernstein
BACKGROUND: Delayed completion of human papillomavirus vaccination (4vHPV) series is common. We sought to identify factors associated with delay. METHODS: This substudy was part of a large prospective, multi-site study recruiting 9-17 year old girls at the time of their third 4vHPV dose to assess immunogenicity associated with prolonged dosing intervals. At participating sites, parents/legal guardians (caregivers) of all enrolled girls (9-17 years old) and enrolled girls aged 14-17 years were approached for participation...
February 7, 2018: Vaccine
https://www.readbyqxmd.com/read/29424799/safety-and-immunogenicity-of-the-hpv-16-18-as04-adjuvanted-vaccine-in-4-6-year-old-girls-results-to-month-12-from-a-randomized-trial
#5
Lan Lin, Mercedes Macias Parra, Victor Y Sierra, Albino Salas Cespedes, Maria Angelica Granados, Adriana Luque, Silvia Damaso, Maria Mercedes Castrejon Alba, Luis Romano-Mazzotti, Frank Struyf
BACKGROUND: The burden of cervical cancer caused by human papillomavirus (HPV) is high in Latin America. The suboptimal HPV vaccination coverage in adolescents could be improved by pediatric immunization. HPV vaccination has not yet been reported in girls aged <9 years. METHODS: This ongoing phase III, controlled, randomized, single-blind, multicenter study conducted in Colombia, Mexico and Panama (NCT01627561) evaluated the safety and immunogenicity of AS04-HPV-16/18 vaccine in 4-6-year-old girls...
February 7, 2018: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/29395515/barriers-to-immunization-among-newcomers-a-systematic-review
#6
Lindsay Wilson, Taylor Rubens-Augustson, Malia Murphy, Cindy Jardine, Natasha Crowcroft, Charles Hui, Kumanan Wilson
INTRODUCTION: Currently, there is a lack of comprehensive evidence exploring vaccine decision-making among newcomers. We conducted a systematic review of qualitative studies aimed at identifying factors that influence newcomers' decision-making with regards to vaccination. METHODS: We conducted a search of MEDLINE, EMBASE, CINAHL and Cochrane Central. To be included, studies needed to employ a qualitative methodology and address newcomer attitudes, beliefs, and/or perceptions regarding vaccination...
January 21, 2018: Vaccine
https://www.readbyqxmd.com/read/29363293/safety-of-hpv-vaccines-in-the-age-of-nonavalent-vaccination
#7
Filippo Quattrone, Alice Canale, Elisa Filippetti, Alberto Tulipani, Andrea Porretta, Pier L Lopalco
To date three vaccines against human papilloma virus (HPV) have been licensed: a bivalent, a quadrivalent and, in 2014, a nonavalent vaccine. Despite the early implementation of national vaccination programs, in the majority of developed countries coverage rates remain unsatisfactory. Rumors about vaccine safety have been one of the principal obstacles for the acceptance of HPV vaccination by the public. It is therefore of primary importance to provide the public with clear and up-to-date information about HPV vaccination safety...
February 2018: Minerva Pediatrica
https://www.readbyqxmd.com/read/29360785/exploring-facilitators-and-barriers-to-initiation-and-completion-of-the-human-papillomavirus-hpv-vaccine-series-among-parents-of-girls-in-a-safety-net-system
#8
Sean T O'Leary, Steven Lockhart, Juliana Barnard, Anna Furniss, Miriam Dickinson, Amanda F Dempsey, Shannon Stokley, Steven Federico, Michael Bronsert, Allison Kempe
Objective: To assess, among parents of predominantly minority, low-income adolescent girls who had either not initiated (NI) or not completed (NC) the HPV vaccine series, attitudes and other factors important in promoting the series, and whether attitudes differed by language preference. Design/Methods: From August 2013-October 2013, we conducted a mail survey among parents of girls aged 12-15 years randomly selected from administrative data in a Denver safety net system; 400 parents from each group (NI and NC) were targeted...
January 23, 2018: International Journal of Environmental Research and Public Health
https://www.readbyqxmd.com/read/29358055/systematic-causality-assessment-of-adverse-events-following-hpv-vaccines-analysis-of-current-data-from-apulia-region-italy
#9
Silvio Tafuri, Francesca Fortunato, Maria Serena Gallone, Pasquale Stefanizzi, Giulia Calabrese, Sara Boccalini, Domenico Martinelli, Rosa Prato
Since 2013, World Health Organization (WHO) recommended that adverse events following immunization (AEFIs) should be evaluated by a standardized algorithm for causality assessment, however the use of WHO procedure is rarely adopted. In Italy, AEFIs (classified only by temporal criteria) are registered in the National Drug Authority (AIFA) database, but causality assessment is not mandatory. Every year AIFA publishes the AEFIs report, that doesn't contain information about causal correlation between events and vaccines...
January 18, 2018: Vaccine
https://www.readbyqxmd.com/read/29333935/association-between-human-papilloma-virus-hpv-vaccination-and-risk-of-multiple-sclerosis-a-systematic-review
#10
Angela Meggiolaro, Giuseppe Migliara, Giuseppe La Torre
INTRODUCTION: The vaccination against Humanpapilloma Virus (HPV) is an effective strategy to prevent high-risk HPV infection and subsequent cervical carcinogenesis. Although the safety profile has been ascertained, the relation with the development of central nervous system (CNS) autoimmune disorders (AD) appears still controversial. Multiple Sclerosis (MS) is the most common cause of chronic neurological impairment in young people, typically striking females. The main purpose of this review was to assess the association between HPV vaccination and MS...
January 15, 2018: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29316817/therapeutic-dna-vaccines-for-human-papillomavirus-and-associated-diseases
#11
Max A Cheng, Emily Farmer, Claire Huang, John Lin, Chien-Fu Hung, T-C Wu
Human papillomavirus (HPV) has long been recognized as the causative agent of cervical cancer. High-risk HPV types 16 and 18 alone, are responsible for over 70% of all cases of cervical cancers. More recently, HPV has been identified as an etiological factor for several other forms of cancers, including oropharyngeal, anogenital, and skin. Thus, the association of HPV with these malignancies creates opportunity for the control of these HPV lesions and HPV-associated malignancies through immunization. Strategies to prevent or to therapeutically treat HPV infections have been developed and are still pushing innovative boundaries...
January 9, 2018: Human Gene Therapy
https://www.readbyqxmd.com/read/29303710/vaccinations-in-adults-with-rheumatoid-arthritis-in-an-era-of-new-disease-modifying-anti-rheumatic-drugs
#12
REVIEW
Pier Luigi Meroni, Daniela Zavaglia, Corrado Girmenia
Patients with rheumatoid arthritis are at greater risk of infectious morbidity and mortality due to disease-related abnormalities and use of immunosuppressive medications. Vaccinations are recommended by international guidelines among infection control strategies, but vaccination rates are reported to be still suboptimal in both America and Europe. Furthermore, with the increasing number of immunomodulatory medications used in RA patients, safety and efficacy of vaccinations in RA patients on such therapies have been questioned...
December 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29280070/safety-of-human-papillomavirus-vaccines-an-updated-review
#13
REVIEW
Anastasia Phillips, Cyra Patel, Alexis Pillsbury, Julia Brotherton, Kristine Macartney
Human papillomavirus (HPV) vaccines are now included in immunisation programmes in 71 countries. Unfortunately, uptake has been impacted in some countries by reduced confidence in the safety of the HPV vaccine. In 2013, we published an extensive review demonstrating a reassuring safety profile for bivalent (2vHPV) and quadrivalent (4vHPV) vaccines. A nonavalent (9vHPV) vaccine is now available and HPV immunisation programmes have been extended to males in 11 countries. The aim of this updated narrative review was to examine the evidence on HPV vaccine safety, focusing on the 9vHPV vaccine, special populations and adverse events of special interest (AESI)...
December 26, 2017: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/29278613/immunogenicity-and-safety-of-the-quadrivalent-human-papillomavirus-vaccine-in-girls-living-with-hiv
#14
Jason Brophy, Ari Bitnun, Ariane Alimenti, Normand Lapointe, Lindy Samson, Stanley Read, Christos Karatzios, Simon Dobson, Erin Moses, Sandra Blitz, Nancy-Grace Lipsky, Gina Ogilvie, Sharon Walmsley, Janet Raboud, Deborah Money
We evaluated quadrivalent HPV (qHPV) vaccine seroresponses among 35 girls living with HIV (ages 9-13) and compared to data on girls without HIV, as part of a subgroup analysis. The qHPV vaccine was safe and well-tolerated. However, antibody response was significantly lower in girls living with HIV relative to girls without HIV. HIV virologic suppression predicted better antibody response. CLINICAL TRIAL REGISTRATION: .
December 22, 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/29258972/characteristics-of-articles-about-human-papillomavirus-vaccination-in-japanese-newspapers-time-series-analysis-study
#15
Nao Ueda, Ryoki Yokouchi, Taro Onoda, Atsushi Ogihara
BACKGROUND: Media coverage and reports have a major influence on individual vaccination and other health-related activities. People use the media to seek information and knowledge on health-related behaviors. They obtain health-related information from media such as television and newspapers, and they trust such information. While several studies have examined the relation between media coverage and individual health, there is a lack of studies that have analyzed media reports of health information...
December 19, 2017: JMIR Public Health and Surveillance
https://www.readbyqxmd.com/read/29211620/safety-profile-of-the-9-valent-human-papillomavirus-vaccine-assessment-in-prior-quadrivalent-hpv-vaccine-recipients-and-in-men-16-to-26%C3%A2-years-of-age
#16
E D Moreira, A R Giuliano, J de Hoon, O-E Iversen, E A Joura, J Restrepo, P Van Damme, C Vandermeulen, M C Ellison, A Krick, C Shields, B Heiles, A Luxembourg
A 9-valent HPV (9vHPV) vaccine has been developed to protect against HPV type 6/11/16/18/31/33/45/52/58-related infection and disease. Previous safety analyses from 7 clinical trials conducted in 9vHPV vaccine recipients 9-26 years of age, including comparisons of 9vHPV and quadrivalent HPV (qHPV) vaccines in girls and women 16-26 years of age, showed that the 9vHPV vaccine was generally well tolerated. Additional safety analyses were conducted to include the results of new clinical studies. The safety profile of the 9vHPV vaccine in prior qHPV vaccine recipients (n = 3756 from 1 randomized controlled trial and 2 open-label extension studies) and young men (n = 248 9vHPV and n = 248 qHPV vaccine recipients from 1 randomized controlled trial) was evaluated...
December 6, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29179869/overcoming-barriers-in-hpv-vaccination-and-screening-programs
#17
Alex Vorsters, Marc Arbyn, Marc Baay, Xavier Bosch, Silvia de Sanjosé, Sharon Hanley, Emilie Karafillakis, Pier Luigi Lopalco, Kevin G Pollock, Joanne Yarwood, Pierre Van Damme
The Human Papillomavirus Prevention and Control Board brought together experts to discuss optimizing HPV vaccination and screening programs. Board members reviewed the safety profile of licensed HPV vaccines based on clinical and post-marketing data, reaching a consensus that current safety data is reassuring. Successful vaccination programs used well-coordinated communication campaigns, integrating (social) media to spread awareness. Communication of evidence supporting vaccine effectiveness had beneficial effects on the perception of the vaccine...
December 2017: Papillomavirus Research
https://www.readbyqxmd.com/read/29174109/comparative-immunogenicity-and-safety-of-human-papillomavirus-hpv-16-18-as04-adjuvanted-vaccine-and-4vhpv-vaccine-administered-according-to-two-or-three-dose-schedules-in-girls-aged-9-14%C3%A2-years-results-to-month-36-from-a-randomized-trial
#18
Ting Fan Leung, Anthony Pak-Yin Liu, Fong Seng Lim, Franck Thollot, Helen May Lin Oh, Bee Wah Lee, Lars Rombo, Ngiap Chuan Tan, Roman Rouzier, Stéphanie De Simoni, Pemmaraju Suryakiran, Marjan Hezareh, Florence Thomas, Nicolas Folschweiller, Frank Struyf
This observer-blind study (clinicaltrials.gov NCT01462357) compared the immunogenicity and safety of two doses (2D) of the HPV-16/18 AS04-adjuvanted vaccine (2D of AS04-HPV-16/18) vs. two or three doses of the 4vHPV vaccine [2D or 3D of 4vHPV] in 1075 healthy girls aged 9-14 years. Girls were randomized (1:1:1) to receive 2D of AS04-HPV-16/18 at months (M) 0, 6 (N = 359), 2D of 4vHPV at M0, 6 (N = 358) or 3D of 4vHPV at M0, 2, 6 (N = 358). 351, 339 and 346 girls, respectively, returned for the concluding visit at M36...
November 23, 2017: Vaccine
https://www.readbyqxmd.com/read/29161198/a-systematic-review-of-factors-influencing-human-papillomavirus-vaccination-among-immigrant-parents-in-the-united-states
#19
Kyounghae Kim, Anna-Rae LeClaire
To critically appraise factors influencing human papillomavirus (HPV) vaccination among immigrant parents in the United States, a comprehensive search of electronic databases and reference lists was conducted. The findings from 22 articles were ordered based on a socio-ecological model. About 30% of children initiated and 14% completed a 3-dose series. Correlates of HPV vaccine initiation rates included lack of information, concerns about vaccine safety and promiscuity, providers' recommendations, school mandates, financial issues, immigration laws, and living in disadvantaged neighborhoods...
November 21, 2017: Health Care for Women International
https://www.readbyqxmd.com/read/29157955/development-of-a-goat-model-for-evaluation-of-withaferin-a-cervical-implants-for-the-treatment-of-cervical-intraepithelial-neoplasia
#20
Leslie C Sherwood, Farrukh Aqil, Manicka V Vadhanam, Jeyaprakash Jeyabalan, Radha Munagala, David Hoetker, Sanjay Srivastava, Inder P Singh, Scott Cambron, Martin O'Toole, Wendy Spencer, Lynn P Parker, Ramesh C Gupta
Cervical cancer is caused by human papillomavirus (HPV). The disease develops over many years through a series of precancerous lesions. Cervical cancer can be prevented by HPV-vaccination, screening and treatment of precancer before development of cervical cancer. The treatment of high-grade cervical dysplasia (CIN(2+)) has traditionally been by cervical conization. Surgical procedures are associated with increased risk of undesirable side effects including bleeding, infection, scarring (stenosis), infertility and complications in later pregnancies...
November 17, 2017: Experimental and Molecular Pathology
keyword
keyword
102610
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"